// STATE LEGISLATION TRACKER

Arkansas HB 1332: TO REQUIRE THE ARKANSAS MEDICAID PROGRAM TO EVALUATE CLAIMS FOR DIAGNOSES FREQUENCY OF OBESITY-RELATED CONDITIONS AND PR

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Failed

State: Arkansas
Bill: HB 1332
Session: 2025
Filed: 2025-01-30
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Arkansas HB1332 would have required Medicaid to study obesity-related diagnoses and costs, with an amended version touching optional coverage for FDA-approved anti-obesity medications. It did not appear to regulate compounded peptides, off-label prescribing, telehealth, naturopathic or NP scope, 503A/503B compounding, controlled substances, or prescription monitoring. Because it died in Senate committee, it creates no current change for peptide users or clinicians.

Key Points

No enacted change to peptide access in Arkansas
No apparent limits on compounded peptides or off-label prescribing
No telehealth, NP, or naturopath scope change indicated
Could have supported obesity-treatment cost transparency
FDA-approved anti-obesity drug coverage was discussed, not passed

What to Watch For

Note Similar obesity-cost reporting bills may return in a future Arkansas session.

✓

Opportunity Future versions could support coverage arguments for FDA-approved GLP-1 weight-loss drugs.

Note This bill does not appear to address compounded GLP-1s or other compounded peptides.

Where the Bill Stands

The bill died in Senate committee at sine die adjournment, so it did not become law.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws